Prognostic Significance of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1) Immunoreactivity in Pancreatic Ductal Adenocarcinoma

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2017 Dec 6

PMID 29202869

Citations 2

Authors

Chihiro Sakugawa

Yukihiro Haruyama

Hiroyuki Tanaka

Tsuyoshi Fukushima

Makiko Kawaguchi

Hiroaki Kataoka

Affiliations

Soon will be listed here.

Abstract

Objective: Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a membrane-bound serine protease inhibitor that is expressed on the surface of epithelial cells. Evidence has suggested that decreased cell surface HAI-1 in carcinoma cells results in enhanced invasiveness. However, little is known regarding the expression of HAI-1 in pancreatic ductal adenocarcinoma (PDAC). This study aimed to analyze HAI-1 expression in PDAC and its impact on patient prognosis.

Results: HAI-1 immunohistochemistry was performed on samples from 67 PDAC cases. HAI-1 expression was increased in intraepithelial neoplasia compared to the adjacent non-neoplastic ductal epithelium. Of the 67 samples tested, 58% (39/67) of PDAC cases showed diffuse (> 75%) immunoreactivity in PDAC cells. The remaining cases showed reduced HAI-1 immunoreactivity in a substantial number of cancer cells. Although there was no correlation between HAI-1 status and tumor size, histologic grade or lymph node metastasis, diffuse HAI-1 positive cases showed longer disease-free survival (DFS; p = 0.006, log-rank test). In conclusion, HAI-1 is upregulated in pancreatic intraepithelial neoplasia and broadly expressed in PDAC cells. However, PDAC cases having areas of reduced HAI-1 immunoreactivity may show shorter DFS.

Citing Articles

Genetics of white color and iridophoroma in "Lemon Frost" leopard geckos.

Guo L, Bloom J, Sykes S, Huang E, Kashif Z, Pham E PLoS Genet. 2021; 17(6):e1009580.

PMID: 34166378 PMC: 8224956. DOI: 10.1371/journal.pgen.1009580.

Decreased expression of SPINT1-AS1 and SPINT1 mRNA might be independent unfavorable prognostic indicators in esophageal squamous cell carcinoma.

Shen F, Pan Y, Yang H, Li J, Zhao F, Su J Onco Targets Ther. 2019; 12:4755-4763.

PMID: 31417276 PMC: 6591775. DOI: 10.2147/OTT.S206448.

References

Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H . Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 2009; 69(5):1828-35. DOI: 10.1158/0008-5472.CAN-08-3728. View

Ye J, Kawaguchi M, Haruyama Y, Kanemaru A, Fukushima T, Yamamoto K . Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model. Cancer Sci. 2013; 105(1):44-51. PMC: 4317873. DOI: 10.1111/cas.12306. View

Domoto T, Takino T, Guo L, Sato H . Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase. Cancer Sci. 2011; 103(3):448-54. PMC: 7713627. DOI: 10.1111/j.1349-7006.2011.02162.x. View

Akerberg D, Ansari D, Andersson R . Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol. 2016; 22(28):6424-33. PMC: 4968124. DOI: 10.3748/wjg.v22.i28.6424. View

Tanabe L, List K . The role of type II transmembrane serine protease-mediated signaling in cancer. FEBS J. 2016; 284(10):1421-1436. PMC: 5432387. DOI: 10.1111/febs.13971. View

Ellenrieder V, Alber B, Lacher U, Hendler S, Menke A, Boeck W . Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer. 1999; 85(1):14-20. DOI: 10.1002/(sici)1097-0215(20000101)85:1<14::aid-ijc3>3.0.co;2-o. View

Rucki A, Foley K, Zhang P, Xiao Q, Kleponis J, Wu A . Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. Cancer Res. 2016; 77(1):41-52. PMC: 5245778. DOI: 10.1158/0008-5472.CAN-16-1383. View

Kataoka H, Suganuma T, Shimomura T, Itoh H, Kitamura N, Nabeshima K . Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem. 1999; 47(5):673-82. DOI: 10.1177/002215549904700509. View

Lin S, Wang J, Saintigny P, Wu C, Giri U, Zhang J . Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014; 15:1079. PMC: 4298954. DOI: 10.1186/1471-2164-15-1079. View

10.

Uhland K, Siphos B, Arkona C, Schuster M, Petri B, Steinmetzer P . Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma. Int J Oncol. 2009; 35(2):347-57. View

11.

Hoshiko S, Kawaguchi M, Fukushima T, Haruyama Y, Yorita K, Tanaka H . Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer Res. 2013; 73(8):2659-70. DOI: 10.1158/0008-5472.CAN-12-3337. View

12.

Wallrapp C, Hahnel S, Burghardt B, Iwamura T, Ruthenburger M, Lerch M . A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 2000; 60(10):2602-6. View

13.

Jung H, Lee K, Park S, Park J, Jang Y, Choi S . TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene. 2007; 27(18):2635-47. DOI: 10.1038/sj.onc.1210914. View

14.

Kang C, Babicky M, Lowy A . The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014; 43(2):183-9. PMC: 4009395. DOI: 10.1097/MPA.0000000000000088. View

15.

Kitajima Y, Ide T, Ohtsuka T, Miyazaki K . Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 2008; 99(7):1341-7. PMC: 11159873. DOI: 10.1111/j.1349-7006.2008.00828.x. View

16.

Fukushima T, Kawaguchi M, Yamasaki M, Tanaka H, Yorita K, Kataoka H . Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci. 2010; 102(2):407-13. PMC: 11159235. DOI: 10.1111/j.1349-7006.2010.01808.x. View

17.

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R . TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011; 6(7):e21650. PMC: 3128608. DOI: 10.1371/journal.pone.0021650. View

18.

Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N . Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem. 2000; 275(51):40453-62. DOI: 10.1074/jbc.M006412200. View

19.

Kawaguchi M, Kataoka H . Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers (Basel). 2014; 6(4):1890-904. PMC: 4276949. DOI: 10.3390/cancers6041890. View

20.

Matsumoto K, Umitsu M, De Silva D, Roy A, Bottaro D . Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. 2017; 108(3):296-307. PMC: 5378267. DOI: 10.1111/cas.13156. View